LACTOBACILLUS BULGARICUS LB-87 Technical Memorandum
Invention behind ProBion is responsible for the remarkable success of ProBion probiotic used as the preferred regimen during recent colon cancer clinical trial published in the BMJ (formerly British Medical Journal) of Open Gastroenterology July 2017. The final outcome showed that 2 x tables of ProBion Clinica a day for an average of 31 days (range: 8 to 78 days) had altered a significant amount of cancer-associated harmful bacteria and generated a plethora of beneficial bacteria with anti-inflammatory effects.
» We are at the forefront in the field of probiotics and human health. At Wasa Medicals we took well researched strains with hundreds of peer review publications and spent last 25 years customising them with patients – ensuring their prolonged effectiveness according to digestive disorders – irrespective of age and sex. Wasa Medicals is a member of International Probiotic Association – IPA.
ProBion is based on science and demonstrated evidence and we follow rigorous scientific process. ProBion tablet disintegration profile has been verified according to the European Pharmacopoeia. This provides common quality standards throughout the pharmaceutical industry in Europe to control the quality of medicines, and the substances used to manufacture them.
We present a Technical Memorandum of Lactobacillus bulgaricus LB-87